it’s less people’s data, sure there is going to be some patient trial records, etc, but this isn’t very interesting as the juicy stuff is probably documented in medical literature anyway.

the big loss to the company would be the synthesis pathways and records of novel molecules that took them many years to research. even just directional research data could speed up rival pharma research. the actual value on keeping this stuff secret is easily in the billions of dollars.